Copper-67 Market Size, Trends & Growth Opportunity By Production Technology, By Application, By End User (Radiopharmaceutical Manufacturers, Nuclear Medicine Centers), By Region and Forecast Till 2030

Report ID : AMR1005914 | Industries : Healthcare | Published On :August 2026 | Page Count : 247

Request Sample
Ask for Customization

The Copper-67 market covers cyclotron-based, linear accelerator-based, reactor-based and accelerator-driven production of Copper-67, along with the Copper-67 chloride, radiolabeled compounds, therapeutic precursors and research-grade and clinical-grade product forms that radiopharmaceutical manufacturers, nuclear medicine centers and biotechnology companies rely on to develop and supply targeted radionuclide therapies.

This market occupies an early-stage but rapidly scaling position within the broader global radiopharmaceutical and theranostics ecosystem, valued for Copper-67's distinctive beta-emission and imaging-compatible decay properties that support both therapeutic and diagnostic use within a single isotope.

The United States anchors established regional demand for this report's scope, with concentrated production and clinical activity across Wisconsin, Illinois, Texas, California and Massachusetts, reflecting the country's dense base of radiopharmaceutical manufacturing and clinical trial infrastructure.

The market spans a wide range of cancer indications and commercial stages, from research-use and preclinical development activity supporting neuroendocrine tumor and prostate cancer programs to the earliest commercial therapeutic deployment now emerging as clinical pipelines mature.

Buyer sophistication continues to rise across this market, with radiopharmaceutical developers and nuclear medicine networks increasingly evaluating suppliers not just on isotope availability but on production reliability, specific activity, product purity and long-term supply security.

As a category, Copper-67 sits at the intersection of nuclear physics production expertise and clinical oncology development, a combination that has made integrated supply chain positioning and clinical partnership capability increasingly strategic considerations within suppliers' commercialization agendas.

This early-stage positioning has also attracted growing interest from investors seeking exposure to the theranostics category more broadly, given Copper-67's distinctive ability to support both therapeutic and diagnostic imaging functions within closely related isotope chemistry.

Producers and developers alike continue to describe the current period as a critical capacity-building phase, with production infrastructure investment decisions made today expected to shape which companies can credibly serve commercial-scale demand once major clinical candidates reach approval.

Suppliers that combine deep nuclear physics production expertise with modern clinical partnership capability have increasingly separated themselves from competitors focused narrowly on production alone.

Buyers evaluating this market for the first time should note that production capability alone rarely determines supplier selection; clinical partnership track record, regulatory documentation quality and demonstrated batch-to-batch consistency typically weigh just as heavily in final sourcing decisions.

Industry participants also increasingly describe Copper-67 supply security as a shared responsibility spanning clinical development, regulatory affairs and supply chain teams, rather than a narrow production function owned by a single department.

Market Size & Growth Forecast (2026 to 2030)

The global Copper-67 market is estimated at approximately USD 180 Million in 2025 and is projected to reach approximately USD 450 Million by 2030, expanding at a compound annual growth rate of roughly 20 percent across the forecast period, reflecting an expanding clinical pipeline of targeted radionuclide therapies and growing theranostic adoption across oncology indications.

This growth trajectory reflects rising government and institutional funding for radiopharmaceutical production infrastructure, alongside increasing biotechnology and pharmaceutical company investment in neuroendocrine tumor and prostate cancer targeted therapy programs requiring dependable isotope supply chains.

Clinical trial supply and commercial therapeutic deployment are expected to grow fastest across the forecast period, as several Copper-67-based therapeutic candidates advance from clinical development toward regulatory approval and early commercial launch.

This growth trajectory should be read against a genuinely small current base; even modest absolute increases in commercial therapeutic deployment can translate into outsized percentage growth relative to today's still-limited clinical-stage revenue.

Production capacity additions announced by leading named producers over the next several years are expected to materially influence how closely actual market growth tracks this forecast, given supply availability's direct bearing on how quickly clinical programs can scale.

Regional demand growth is expected to track closely with clinical trial site expansion over the forecast period, meaning countries hosting the most active neuroendocrine tumor and prostate cancer trial programs are also likely to see the steepest near-term supply investment.

MetricValue
Market Size (2025)Approximately USD 180 Million
Forecast Size (2030)Approximately USD 450 Million
CAGR (2025-2030)Approximately 20%
Base Year2025
Forecast Period2026-2030 (5-year)
Largest Application SegmentTargeted radionuclide therapy for neuroendocrine tumors and prostate cancer
Fastest-Growing SegmentClinical trial supply and commercial therapeutic deployment
Leading Regional Demand CenterUnited States and Europe
Key Growth DriverExpanding clinical pipeline of targeted radionuclide therapies and theranostic adoption
Market StructureModerately concentrated, with a small number of specialized isotope producers alongside integrated pharmaceutical developers

Market Drivers

Expanding clinical pipeline of targeted radionuclide therapies driving sustained demand for reliable, high-purity Copper-67 supply.

Growing theranostic adoption across oncology indications increasing demand for Copper-67 alongside companion diagnostic isotopes.

Rising government and institutional funding for radiopharmaceutical production infrastructure favoring producers with proven cyclotron and accelerator-based capacity.

Increasing biotechnology and pharmaceutical company investment in neuroendocrine tumor and prostate cancer targeted therapy programs requiring dependable isotope supply chains.

Growing recognition among oncology drug developers that theranostic pairing can meaningfully de-risk clinical development, by allowing early diagnostic confirmation of target engagement before committing to full therapeutic dosing, has further reinforced demand for Copper-67-based programs.

Growing collaboration between academic medical centers and commercial developers has further reinforced the clinical evidence base supporting expanded Copper-67 investment across a widening range of oncology indications.

Market Restraints

High technical complexity and capital intensity of cyclotron and accelerator-based production limiting the pace at which new suppliers can enter the market.

Limited global production capacity constraining supply availability relative to accelerating clinical trial demand.

Extended regulatory approval pathways for clinical and commercial therapeutic supply slowing new supplier qualification cycles.

Specific activity and product purity requirements continuing to raise the technical bar for producers serving commercial therapeutic applications.

The market's current reliance on a comparatively small number of qualified production facilities also introduces a degree of supply concentration risk that developers must actively manage within their own clinical trial planning.

Talent scarcity in specialized radiochemistry and nuclear production engineering disciplines has also emerged as a meaningful constraint, with several producers reporting longer hiring timelines for qualified technical staff than for comparable pharmaceutical manufacturing roles.

Market Opportunities

Considerable untapped opportunity in production capacity expansion as clinical demand continues to outpace current global supply.

Growing theranostic pipeline development offering producers differentiated positioning beyond single-isotope supply relationships.

Expanding regional production capability in Asia-Pacific and Europe offering suppliers meaningful geographic diversification potential.

Emerging cancer indications beyond neuroendocrine tumors and prostate cancer creating new addressable clinical demand for targeted radionuclide therapy.

Academic and government research institutions expanding their own isotope production capability represent a further, less commercially visible avenue for capacity growth that could meaningfully ease near-term supply constraints.

Partnerships between isotope producers and academic medical centers, embedding early production access directly into institutional research infrastructure, represent a further avenue for meaningful market expansion over the coming years.

Vendors offering flexible, milestone-based supply agreements have found this structure particularly effective at winning early relationships with smaller developers hesitant to commit to large upfront volume purchases before clinical results are known.

Copper-67 Production Technologies and Product Forms

The market spans cyclotron-based, linear accelerator-based, reactor-based and accelerator-driven production, each mapped against Copper-67 chloride, radiolabeled compounds and research-grade through clinical-grade product forms. Full segmentation detail is covered on the production technologies and product forms page.

Copper-67 Applications and Cancer Indications

Targeted radionuclide therapy, oncology therapeutics and theranostic applications each connect to distinct cancer indications spanning neuroendocrine tumors through other solid tumors. Full detail is covered on the applications and cancer indications page.

Copper-67 End Users and Commercial Stages

Radiopharmaceutical manufacturers, nuclear medicine centers and academic research institutes each connect to distinct commercial stages spanning research use through commercial therapeutic deployment. Full detail is covered on the end users and commercial stages page.

Copper-67 Regulatory Classifications

Investigational use, clinical trial supply and commercial therapeutic supply each carry distinct regulatory requirements shaping supplier qualification. Full detail is covered on the regulatory classifications page.

Copper-67 Market, By Region

North America, anchored by the United States, represents the market's most established regional demand center, reflecting Wisconsin, Illinois, Texas, California and Massachusetts' dense base of radiopharmaceutical manufacturing and clinical trial infrastructure, with Canada's Ontario and Quebec contributing meaningful research and production capacity.

Europe, anchored by Germany, France, Switzerland and the United Kingdom, sustains significant demand tied to established radiopharmaceutical development and nuclear medicine networks and stringent clinical and regulatory compliance requirements.

Asia-Pacific, anchored by Japan, South Korea and China, represents a growing regional demand center given the region's expanding investment in radiopharmaceutical manufacturing and clinical research infrastructure.

Across all regions, commercial stage and regulatory classification continue to shape the balance between research-use and clinical-trial-supply demand within each country's overall procurement mix.

Government-funded isotope production initiatives in several countries have begun meaningfully shaping regional supply capacity, reflecting growing recognition of radioisotope production as a strategic national research and healthcare infrastructure priority.

Leading Companies

NorthStar Medical Radioisotopes, Nusano, Curium, ITM Isotope Technologies Munich and Telix Pharmaceuticals together shape the market's competitive landscape. A full, non-ranked overview of the companies leading the Copper-67 market is available on our companies page.

Beyond This Page

Radiopharmaceutical developers and nuclear medicine centers making a supplier-selection decision on the strength of the public segmentation covered on these pages alone are working from directional signal rather than decision-grade detail. Category-level description of production technologies, applications and regulatory classifications explains the shape of this market, but it does not tell a radiopharmaceutical developer which specific named producer holds the strongest clinical-grade supply record for a given indication, what a comparable long-term manufacturing partnership is actually priced at, or how a specific biotechnology company moves through its own supplier qualification cycle, the detail a Copper-67 sourcing decision genuinely depends on.

That gap has real consequences at the point a buyer commits clinical development or procurement budget to this market. Without the buyer intelligence, competitive benchmarking and company-level profiles the full report adds, a decision-maker is left choosing which production technology to prioritize, which cancer indication to pursue, or which supplier relationship to standardize on category-level description alone, a considerably weaker basis for that decision than the underlying report data provides.

Buyers proceeding on directional signal alone risk misallocating clinical development budget toward the wrong production technology, application focus or supplier relationship relative to what a fully informed, data-backed decision would support.

Frequently Asked Questions

The market is estimated at approximately USD 180 million in 2025 and is projected to reach approximately USD 450 million by 2030, growing at around 20 percent annually.

An expanding clinical pipeline of targeted radionuclide therapies, growing theranostic adoption across oncology indications, and rising government and institutional funding for radiopharmaceutical production infrastructure are the primary drivers.

Copper-67 is a therapeutic radioisotope used in targeted radionuclide therapy and theranostic applications, primarily in oncology indications such as neuroendocrine tumors, prostate cancer and other solid tumors.

NorthStar Medical Radioisotopes, Nusano and Curium are among the leading companies, alongside specialized producers and developers including ITM Isotope Technologies Munich, Telix Pharmaceuticals and Orano Med.

North America leads regional demand given the United States' dense base of radiopharmaceutical manufacturing and clinical trial infrastructure, with Europe representing a significant secondary demand center tied to established nuclear medicine networks.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Global Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Expanding Clinical Pipeline of Targeted Radionuclide Therapies Driving Sustained Demand for Reliable, High-Purity Copper-67 Supply.

3.3.2. Growing Theranostic Adoption Across Oncology Indications Increasing Demand for Copper-67 Alongside Companion Diagnostic Isotopes.

3.3.3. Rising Government and Institutional Funding for Radiopharmaceutical Production Infrastructure Favoring Producers with Proven Cyclotron and Accelerator-Based Capacity.

3.3.4. Increasing Biotechnology and Pharmaceutical Company Investment in Neuroendocrine Tumor and Prostate Cancer Targeted Therapy Programs Requiring Dependable Isotope Supply Chains.

3.4. Restraints

3.4.1. High Technical Complexity and Capital Intensity of Cyclotron and Accelerator-Based Production Limiting the Pace at Which New Suppliers Can Enter the Market.

3.4.2. Limited Global Production Capacity Constraining Supply Availability Relative to Accelerating Clinical Trial Demand.

3.4.3. Extended Regulatory Approval Pathways for Clinical and Commercial Therapeutic Supply Slowing New Supplier Qualification Cycles.

3.4.4. Specific Activity and Product Purity Requirements Continuing to Raise the Technical Bar for Producers Serving Commercial Therapeutic Applications.

3.5. Opportunities

3.5.1. Considerable Untapped Opportunity in Production Capacity Expansion as Clinical Demand Continues to Outpace Current Global Supply.

3.5.2. Growing Theranostic Pipeline Development Offering Producers Differentiated Positioning Beyond Single-Isotope Supply Relationships.

3.5.3. Expanding Regional Production Capability in Asia-Pacific and Europe Offering Suppliers Meaningful Geographic Diversification Potential.

3.5.4. Emerging Cancer Indications Beyond Neuroendocrine Tumors and Prostate Cancer Creating New Addressable Clinical Demand for Targeted Radionuclide Therapy.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains, Production Technology

4.1. Cyclotron-Based Production

4.2. Linear Accelerator (LINAC)-Based Production

4.3. Reactor-Based Production

4.4. Accelerator-Driven Technologies

4.5. Emerging Production Pathways

5. Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains, Product Form

5.1. Copper-67 Chloride

5.2. Copper-67 Radiolabeled Compounds

5.3. Therapeutic Copper-67 Precursors

5.4. Research-Grade Copper-67

5.5. Clinical-Grade Copper-67

6. Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains, Application

6.1. Targeted Radionuclide Therapy

6.2. Oncology Therapeutics

6.3. Theranostic Applications

6.4. Clinical Research

6.5. Translational Research

6.6. Drug Development Programs

7. Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains, Cancer Indication

7.1. Neuroendocrine Tumors

7.2. Prostate Cancer

7.3. Breast Cancer

7.4. Lymphoma

7.5. Colorectal Cancer

7.6. Ovarian Cancer

7.7. Pancreatic Cancer

7.8. Other Solid Tumors

8. Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains, End User

8.1. Radiopharmaceutical Manufacturers

8.2. Nuclear Medicine Centers

8.3. Academic Research Institutes

8.4. Contract Research Organizations

8.5. Biotechnology Companies

8.6. Pharmaceutical Companies

8.7. Government Research Organizations

9. Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains, Commercial Stage

9.1. Research Use

9.2. Preclinical Development

9.3. Clinical Development

9.4. Commercial Therapeutic Deployment

10. Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains, Regulatory Classification

10.1. Investigational Use

10.2. Clinical Trial Supply

10.3. Commercial Therapeutic Supply

11. Buyer Intelligence and Demand Landscape

11.1. Buyer Segmentation

11.1.1. Radiopharmaceutical Developers

11.1.2. Nuclear Medicine Networks

11.1.3. Pharmaceutical Manufacturers

11.1.4. Academic Medical Centers

11.1.5. Government Research Institutions

11.2. Buyer Industry Analysis

11.2.1. Nuclear Medicine

11.2.2. Oncology

11.2.3. Precision Medicine

11.2.4. Biotechnology

11.2.5. Drug Development

11.3. Buyer Company Classification

11.3.1. Global Pharmaceutical Companies

11.3.2. Specialty Radiopharmaceutical Companies

11.3.3. Clinical Research Organizations

11.3.4. University Medical Centers

11.3.5. Government Research Laboratories

11.4. Buyer Concentration and Regional Clusters

11.4.1. United States Radiopharmaceutical Manufacturing Concentration (Wisconsin, Illinois, Texas)

11.4.2. European Nuclear Medicine and Isotope Production Concentration (Germany, France, Switzerland)

11.4.3. Asia-Pacific Emerging Radiopharmaceutical Market Concentration (Japan, South Korea, China)

11.4.4. Canadian Isotope Production and Research Clusters (Ontario, Quebec)

11.4.5. California and Massachusetts Biotechnology and Clinical Research Hubs

11.5. Procurement Models

11.5.1. Direct Isotope Supply Agreements

11.5.2. Long-Term Manufacturing Partnerships

11.5.3. Clinical Trial Supply Contracts

11.5.4. Research Procurement Programs

11.6. Buying Triggers

11.6.1. Clinical Trial Expansion

11.6.2. New Therapeutic Programs

11.6.3. Regulatory Milestones

11.6.4. Supply Chain Diversification

11.6.5. Theranostic Pipeline Development

11.7. Decision Makers

11.7.1. CEO

11.7.2. CSO

11.7.3. Head of Radiopharmaceutical Development

11.7.4. Nuclear Medicine Director

11.7.5. Clinical Operations Leadership

11.7.6. Procurement Leadership

11.8. Budget Ownership and Vendor Selection

11.8.1. Radiopharmaceutical Development Budgets

11.8.2. Clinical Operations and Supply Chain Budgets

11.8.3. Isotope Availability

11.8.4. Production Reliability

11.8.5. Regulatory Compliance

11.8.6. Specific Activity

11.8.7. Product Purity

11.8.8. Logistics Capabilities

11.9. Contract Value Bands and Sales Cycle

11.9.1. Research Procurement Program Agreements

11.9.2. Clinical Trial Supply Contracts

11.9.3. Long-Term Manufacturing Partnership Agreements

11.9.4. Extended Clinical and Regulatory Milestone-Driven Sales Cycles

11.9.5. Faster Research-Use Procurement Cycles

11.10. Strategic Relevance for NorthStar Medical Radioisotopes

11.10.1. Production Capacity Expansion Opportunities

11.10.2. Regional Coverage Expansion Opportunities

11.10.3. Emerging Theranostic Segment Opportunities

11.10.4. Clinical Supply Differentiation Opportunities

12. Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains, By Region

12.1. North America

12.2. Europe

12.3. Asia-Pacific

13. North America Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains Market Analysis and Forecast (2026–2030)

13.1. Introduction

13.2. Market Share Analysis

13.3. Market Size and Forecast

13.4. Market Size and Forecast, By Geography

13.4.1. United States

13.4.1.1. Market Share Analysis

13.4.1.2. Market Size and Forecast

13.4.1.3. By Product

13.4.1.4. By Technology

13.4.1.5. By Application

13.4.1.6. By Customer

13.4.1.7. Wisconsin

13.4.1.7.1. Market Share Analysis

13.4.1.7.2. Market Size and Forecast

13.4.1.7.3. By Product

13.4.1.7.4. By Technology

13.4.1.7.5. By Application

13.4.1.7.6. By Customer

13.4.1.8. Illinois

13.4.1.8.1. Market Share Analysis

13.4.1.8.2. Market Size and Forecast

13.4.1.8.3. By Product

13.4.1.8.4. By Technology

13.4.1.8.5. By Application

13.4.1.8.6. By Customer

13.4.1.9. Texas

13.4.1.9.1. Market Share Analysis

13.4.1.9.2. Market Size and Forecast

13.4.1.9.3. By Product

13.4.1.9.4. By Technology

13.4.1.9.5. By Application

13.4.1.9.6. By Customer

13.4.1.10. California

13.4.1.10.1. Market Share Analysis

13.4.1.10.2. Market Size and Forecast

13.4.1.10.3. By Product

13.4.1.10.4. By Technology

13.4.1.10.5. By Application

13.4.1.10.6. By Customer

13.4.1.11. Massachusetts

13.4.1.11.1. Market Share Analysis

13.4.1.11.2. Market Size and Forecast

13.4.1.11.3. By Product

13.4.1.11.4. By Technology

13.4.1.11.5. By Application

13.4.1.11.6. By Customer

13.4.1.12. Pennsylvania

13.4.1.12.1. Market Share Analysis

13.4.1.12.2. Market Size and Forecast

13.4.1.12.3. By Product

13.4.1.12.4. By Technology

13.4.1.12.5. By Application

13.4.1.12.6. By Customer

13.4.1.13. New Jersey

13.4.1.13.1. Market Share Analysis

13.4.1.13.2. Market Size and Forecast

13.4.1.13.3. By Product

13.4.1.13.4. By Technology

13.4.1.13.5. By Application

13.4.1.13.6. By Customer

13.4.2. Canada

13.4.2.1. Market Share Analysis

13.4.2.2. Market Size and Forecast

13.4.2.3. By Product

13.4.2.4. By Technology

13.4.2.5. By Application

13.4.2.6. By Customer

13.4.2.7. Ontario

13.4.2.7.1. Market Share Analysis

13.4.2.7.2. Market Size and Forecast

13.4.2.7.3. By Product

13.4.2.7.4. By Technology

13.4.2.7.5. By Application

13.4.2.7.6. By Customer

13.4.2.8. Quebec

13.4.2.8.1. Market Share Analysis

13.4.2.8.2. Market Size and Forecast

13.4.2.8.3. By Product

13.4.2.8.4. By Technology

13.4.2.8.5. By Application

13.4.2.8.6. By Customer

14. Europe Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains Market Analysis and Forecast (2026–2030)

14.1. Introduction

14.2. Market Share Analysis

14.3. Market Size and Forecast

14.4. Market Size and Forecast, By Geography

14.4.1. Germany

14.4.1.1. Market Share Analysis

14.4.1.2. Market Size and Forecast

14.4.1.3. By Product

14.4.1.4. By Technology

14.4.1.5. By Application

14.4.1.6. By Customer

14.4.2. France

14.4.2.1. Market Share Analysis

14.4.2.2. Market Size and Forecast

14.4.2.3. By Product

14.4.2.4. By Technology

14.4.2.5. By Application

14.4.2.6. By Customer

14.4.3. United Kingdom

14.4.3.1. Market Share Analysis

14.4.3.2. Market Size and Forecast

14.4.3.3. By Product

14.4.3.4. By Technology

14.4.3.5. By Application

14.4.3.6. By Customer

14.4.4. Netherlands

14.4.4.1. Market Share Analysis

14.4.4.2. Market Size and Forecast

14.4.4.3. By Product

14.4.4.4. By Technology

14.4.4.5. By Application

14.4.4.6. By Customer

14.4.5. Belgium

14.4.5.1. Market Share Analysis

14.4.5.2. Market Size and Forecast

14.4.5.3. By Product

14.4.5.4. By Technology

14.4.5.5. By Application

14.4.5.6. By Customer

14.4.6. Switzerland

14.4.6.1. Market Share Analysis

14.4.6.2. Market Size and Forecast

14.4.6.3. By Product

14.4.6.4. By Technology

14.4.6.5. By Application

14.4.6.6. By Customer

14.4.7. Italy

14.4.7.1. Market Share Analysis

14.4.7.2. Market Size and Forecast

14.4.7.3. By Product

14.4.7.4. By Technology

14.4.7.5. By Application

14.4.7.6. By Customer

15. Asia-Pacific Copper-67 Market - Global View with Focus on Therapeutic Radioisotopes, Radiopharmaceutical Development, Targeted Radionuclide Therapy and Nuclear Medicine Supply Chains Market Analysis and Forecast (2026–2030)

15.1. Introduction

15.2. Market Share Analysis

15.3. Market Size and Forecast

15.4. Market Size and Forecast, By Geography

15.4.1. Japan

15.4.1.1. Market Share Analysis

15.4.1.2. Market Size and Forecast

15.4.1.3. By Product

15.4.1.4. By Technology

15.4.1.5. By Application

15.4.1.6. By Customer

15.4.2. South Korea

15.4.2.1. Market Share Analysis

15.4.2.2. Market Size and Forecast

15.4.2.3. By Product

15.4.2.4. By Technology

15.4.2.5. By Application

15.4.2.6. By Customer

15.4.3. China

15.4.3.1. Market Share Analysis

15.4.3.2. Market Size and Forecast

15.4.3.3. By Product

15.4.3.4. By Technology

15.4.3.5. By Application

15.4.3.6. By Customer

15.4.4. Australia

15.4.4.1. Market Share Analysis

15.4.4.2. Market Size and Forecast

15.4.4.3. By Product

15.4.4.4. By Technology

15.4.4.5. By Application

15.4.4.6. By Customer

15.4.5. India

15.4.5.1. Market Share Analysis

15.4.5.2. Market Size and Forecast

15.4.5.3. By Product

15.4.5.4. By Technology

15.4.5.5. By Application

15.4.5.6. By Customer

16. Competition Analysis

16.1. Market Positioning Overview

16.1.1. Label

16.1.2. Items

16.2. Competitive Benchmarking Metrics

16.2.1. Label

16.2.2. Items

16.3. Strategic Moves

16.3.1. Label

16.3.2. Items

16.4. Competitive Mapping & Gaps

16.4.1. Label

16.4.2. Items

17. Company Profiles

17.1. NorthStar Medical Radioisotopes

17.1.1. Company Overview

17.1.2. Headquarters, Ownership and Workforce

17.1.3. Geographic Footprint

17.1.4. Radiopharmaceutical Portfolio

17.1.5. Copper-67 Related Activities

17.1.6. Production Technologies

17.1.7. Manufacturing Infrastructure

17.1.8. Target Customer Segments

17.1.9. Distribution and Commercial Strategy

17.1.10. Key Financial Indicators

17.1.11. Certifications and Regulatory Compliance

17.1.12. Strategic Partnerships

17.1.13. R&D Initiatives

17.1.14. Recent Developments

17.1.15. SWOT Analysis

17.2. Nusano

17.2.1. Company Overview

17.2.2. Headquarters, Ownership and Workforce

17.2.3. Geographic Footprint

17.2.4. Radiopharmaceutical Portfolio

17.2.5. Copper-67 Related Activities

17.2.6. Production Technologies

17.2.7. Manufacturing Infrastructure

17.2.8. Target Customer Segments

17.2.9. Distribution and Commercial Strategy

17.2.10. Key Financial Indicators

17.2.11. Certifications and Regulatory Compliance

17.2.12. Strategic Partnerships

17.2.13. R&D Initiatives

17.2.14. Recent Developments

17.2.15. SWOT Analysis

17.3. TerraPower Isotopes

17.3.1. Company Overview

17.3.2. Headquarters, Ownership and Workforce

17.3.3. Geographic Footprint

17.3.4. Radiopharmaceutical Portfolio

17.3.5. Copper-67 Related Activities

17.3.6. Production Technologies

17.3.7. Manufacturing Infrastructure

17.3.8. Target Customer Segments

17.3.9. Distribution and Commercial Strategy

17.3.10. Key Financial Indicators

17.3.11. Certifications and Regulatory Compliance

17.3.12. Strategic Partnerships

17.3.13. R&D Initiatives

17.3.14. Recent Developments

17.3.15. SWOT Analysis

17.4. Niowave

17.4.1. Company Overview

17.4.2. Headquarters, Ownership and Workforce

17.4.3. Geographic Footprint

17.4.4. Radiopharmaceutical Portfolio

17.4.5. Copper-67 Related Activities

17.4.6. Production Technologies

17.4.7. Manufacturing Infrastructure

17.4.8. Target Customer Segments

17.4.9. Distribution and Commercial Strategy

17.4.10. Key Financial Indicators

17.4.11. Certifications and Regulatory Compliance

17.4.12. Strategic Partnerships

17.4.13. R&D Initiatives

17.4.14. Recent Developments

17.4.15. SWOT Analysis

17.5. ITM Isotope Technologies Munich

17.5.1. Company Overview

17.5.2. Headquarters, Ownership and Workforce

17.5.3. Geographic Footprint

17.5.4. Radiopharmaceutical Portfolio

17.5.5. Copper-67 Related Activities

17.5.6. Production Technologies

17.5.7. Manufacturing Infrastructure

17.5.8. Target Customer Segments

17.5.9. Distribution and Commercial Strategy

17.5.10. Key Financial Indicators

17.5.11. Certifications and Regulatory Compliance

17.5.12. Strategic Partnerships

17.5.13. R&D Initiatives

17.5.14. Recent Developments

17.5.15. SWOT Analysis

17.6. Curium

17.6.1. Company Overview

17.6.2. Headquarters, Ownership and Workforce

17.6.3. Geographic Footprint

17.6.4. Radiopharmaceutical Portfolio

17.6.5. Copper-67 Related Activities

17.6.6. Production Technologies

17.6.7. Manufacturing Infrastructure

17.6.8. Target Customer Segments

17.6.9. Distribution and Commercial Strategy

17.6.10. Key Financial Indicators

17.6.11. Certifications and Regulatory Compliance

17.6.12. Strategic Partnerships

17.6.13. R&D Initiatives

17.6.14. Recent Developments

17.6.15. SWOT Analysis

17.7. Eckert & Ziegler

17.7.1. Company Overview

17.7.2. Headquarters, Ownership and Workforce

17.7.3. Geographic Footprint

17.7.4. Radiopharmaceutical Portfolio

17.7.5. Copper-67 Related Activities

17.7.6. Production Technologies

17.7.7. Manufacturing Infrastructure

17.7.8. Target Customer Segments

17.7.9. Distribution and Commercial Strategy

17.7.10. Key Financial Indicators

17.7.11. Certifications and Regulatory Compliance

17.7.12. Strategic Partnerships

17.7.13. R&D Initiatives

17.7.14. Recent Developments

17.7.15. SWOT Analysis

17.8. IONETIX

17.8.1. Company Overview

17.8.2. Headquarters, Ownership and Workforce

17.8.3. Geographic Footprint

17.8.4. Radiopharmaceutical Portfolio

17.8.5. Copper-67 Related Activities

17.8.6. Production Technologies

17.8.7. Manufacturing Infrastructure

17.8.8. Target Customer Segments

17.8.9. Distribution and Commercial Strategy

17.8.10. Key Financial Indicators

17.8.11. Certifications and Regulatory Compliance

17.8.12. Strategic Partnerships

17.8.13. R&D Initiatives

17.8.14. Recent Developments

17.8.15. SWOT Analysis

17.9. RadioMedix

17.9.1. Company Overview

17.9.2. Headquarters, Ownership and Workforce

17.9.3. Geographic Footprint

17.9.4. Radiopharmaceutical Portfolio

17.9.5. Copper-67 Related Activities

17.9.6. Production Technologies

17.9.7. Manufacturing Infrastructure

17.9.8. Target Customer Segments

17.9.9. Distribution and Commercial Strategy

17.9.10. Key Financial Indicators

17.9.11. Certifications and Regulatory Compliance

17.9.12. Strategic Partnerships

17.9.13. R&D Initiatives

17.9.14. Recent Developments

17.9.15. SWOT Analysis

17.10. Bayer Radiology / Noria Therapeutics Programs

17.10.1. Company Overview

17.10.2. Headquarters, Ownership and Workforce

17.10.3. Geographic Footprint

17.10.4. Radiopharmaceutical Portfolio

17.10.5. Copper-67 Related Activities

17.10.6. Production Technologies

17.10.7. Manufacturing Infrastructure

17.10.8. Target Customer Segments

17.10.9. Distribution and Commercial Strategy

17.10.10. Key Financial Indicators

17.10.11. Certifications and Regulatory Compliance

17.10.12. Strategic Partnerships

17.10.13. R&D Initiatives

17.10.14. Recent Developments

17.10.15. SWOT Analysis

17.11. Telix Pharmaceuticals

17.11.1. Company Overview

17.11.2. Headquarters, Ownership and Workforce

17.11.3. Geographic Footprint

17.11.4. Radiopharmaceutical Portfolio

17.11.5. Copper-67 Related Activities

17.11.6. Production Technologies

17.11.7. Manufacturing Infrastructure

17.11.8. Target Customer Segments

17.11.9. Distribution and Commercial Strategy

17.11.10. Key Financial Indicators

17.11.11. Certifications and Regulatory Compliance

17.11.12. Strategic Partnerships

17.11.13. R&D Initiatives

17.11.14. Recent Developments

17.11.15. SWOT Analysis

17.12. Orano Med

17.12.1. Company Overview

17.12.2. Headquarters, Ownership and Workforce

17.12.3. Geographic Footprint

17.12.4. Radiopharmaceutical Portfolio

17.12.5. Copper-67 Related Activities

17.12.6. Production Technologies

17.12.7. Manufacturing Infrastructure

17.12.8. Target Customer Segments

17.12.9. Distribution and Commercial Strategy

17.12.10. Key Financial Indicators

17.12.11. Certifications and Regulatory Compliance

17.12.12. Strategic Partnerships

17.12.13. R&D Initiatives

17.12.14. Recent Developments

17.12.15. SWOT Analysis

17.13. Isotopia Molecular Imaging

17.13.1. Company Overview

17.13.2. Headquarters, Ownership and Workforce

17.13.3. Geographic Footprint

17.13.4. Radiopharmaceutical Portfolio

17.13.5. Copper-67 Related Activities

17.13.6. Production Technologies

17.13.7. Manufacturing Infrastructure

17.13.8. Target Customer Segments

17.13.9. Distribution and Commercial Strategy

17.13.10. Key Financial Indicators

17.13.11. Certifications and Regulatory Compliance

17.13.12. Strategic Partnerships

17.13.13. R&D Initiatives

17.13.14. Recent Developments

17.13.15. SWOT Analysis

17.14. Advanced Accelerator Applications (Novartis)

17.14.1. Company Overview

17.14.2. Headquarters, Ownership and Workforce

17.14.3. Geographic Footprint

17.14.4. Radiopharmaceutical Portfolio

17.14.5. Copper-67 Related Activities

17.14.6. Production Technologies

17.14.7. Manufacturing Infrastructure

17.14.8. Target Customer Segments

17.14.9. Distribution and Commercial Strategy

17.14.10. Key Financial Indicators

17.14.11. Certifications and Regulatory Compliance

17.14.12. Strategic Partnerships

17.14.13. R&D Initiatives

17.14.14. Recent Developments

17.14.15. SWOT Analysis

17.15. Clarity Pharmaceuticals

17.15.1. Company Overview

17.15.2. Headquarters, Ownership and Workforce

17.15.3. Geographic Footprint

17.15.4. Radiopharmaceutical Portfolio

17.15.5. Copper-67 Related Activities

17.15.6. Production Technologies

17.15.7. Manufacturing Infrastructure

17.15.8. Target Customer Segments

17.15.9. Distribution and Commercial Strategy

17.15.10. Key Financial Indicators

17.15.11. Certifications and Regulatory Compliance

17.15.12. Strategic Partnerships

17.15.13. R&D Initiatives

17.15.14. Recent Developments

17.15.15. SWOT Analysis

17.16. PanTera

17.16.1. Company Overview

17.16.2. Headquarters, Ownership and Workforce

17.16.3. Geographic Footprint

17.16.4. Radiopharmaceutical Portfolio

17.16.5. Copper-67 Related Activities

17.16.6. Production Technologies

17.16.7. Manufacturing Infrastructure

17.16.8. Target Customer Segments

17.16.9. Distribution and Commercial Strategy

17.16.10. Key Financial Indicators

17.16.11. Certifications and Regulatory Compliance

17.16.12. Strategic Partnerships

17.16.13. R&D Initiatives

17.16.14. Recent Developments

17.16.15. SWOT Analysis

17.17. TerraPower

17.17.1. Company Overview

17.17.2. Headquarters, Ownership and Workforce

17.17.3. Geographic Footprint

17.17.4. Radiopharmaceutical Portfolio

17.17.5. Copper-67 Related Activities

17.17.6. Production Technologies

17.17.7. Manufacturing Infrastructure

17.17.8. Target Customer Segments

17.17.9. Distribution and Commercial Strategy

17.17.10. Key Financial Indicators

17.17.11. Certifications and Regulatory Compliance

17.17.12. Strategic Partnerships

17.17.13. R&D Initiatives

17.17.14. Recent Developments

17.17.15. SWOT Analysis

17.18. SHINE Technologies

17.18.1. Company Overview

17.18.2. Headquarters, Ownership and Workforce

17.18.3. Geographic Footprint

17.18.4. Radiopharmaceutical Portfolio

17.18.5. Copper-67 Related Activities

17.18.6. Production Technologies

17.18.7. Manufacturing Infrastructure

17.18.8. Target Customer Segments

17.18.9. Distribution and Commercial Strategy

17.18.10. Key Financial Indicators

17.18.11. Certifications and Regulatory Compliance

17.18.12. Strategic Partnerships

17.18.13. R&D Initiatives

17.18.14. Recent Developments

17.18.15. SWOT Analysis

Frequently Asked Questions

The market is estimated at approximately USD 180 million in 2025 and is projected to reach approximately USD 450 million by 2030, growing at around 20 percent annually.

An expanding clinical pipeline of targeted radionuclide therapies, growing theranostic adoption across oncology indications, and rising government and institutional funding for radiopharmaceutical production infrastructure are the primary drivers.

Copper-67 is a therapeutic radioisotope used in targeted radionuclide therapy and theranostic applications, primarily in oncology indications such as neuroendocrine tumors, prostate cancer and other solid tumors.

NorthStar Medical Radioisotopes, Nusano and Curium are among the leading companies, alongside specialized producers and developers including ITM Isotope Technologies Munich, Telix Pharmaceuticals and Orano Med.

North America leads regional demand given the United States' dense base of radiopharmaceutical manufacturing and clinical trial infrastructure, with Europe representing a significant secondary demand center tied to established nuclear medicine networks.

Inquire Before Buying Request Free Sample Ask For Discount

Public market anchors

The broader medical isotope market was estimated at approximately USD 6.0 billion in 2025, projected to reach USD 9.1 billion by 2030 at roughly 8.6% CAGR. The radiopharmaceuticals market separately was estimated to add approximately USD 7.76 billion in absolute growth from 2025 to 2030 at roughly 12.3% CAGR, and the radiotheranostics market was valued at approximately USD 11.8 billion in 2025, projected to grow at roughly 9.6% CAGR.

Segment narrowing

This report's scope covers Copper-67 specifically, a single therapeutic radioisotope still in an early-stage but rapidly scaling commercial phase, rather than the broader medical isotope, radiopharmaceutical or radiotheranostics categories as a whole, positioning its total addressable market considerably below these broader reference points while reflecting a substantially higher growth rate typical of an isotope moving from clinical development toward early commercial deployment.

Base-year estimation

The resulting market estimate of approximately USD 180 million for 2025 reflects Copper-67's current concentration in research-use, preclinical and early clinical-trial-supply activity, cross-checked against known production capacity investment among leading named producers including NorthStar Medical Radioisotopes and Nusano.

Growth rate derivation

The forecast CAGR of approximately 20% sits meaningfully above the broader radiopharmaceuticals market CAGR of 12.3% and the medical isotope market CAGR of 8.6%, reflecting the small-base effect typical of an emerging therapeutic isotope alongside this report's own drivers around expanding clinical trial supply and approaching commercial therapeutic deployment, consistent with the growth pattern observed in other early-stage therapeutic radioisotopes as they approach commercial launch.

Frequently Asked Questions

The market is estimated at approximately USD 180 million in 2025 and is projected to reach approximately USD 450 million by 2030, growing at around 20 percent annually.

An expanding clinical pipeline of targeted radionuclide therapies, growing theranostic adoption across oncology indications, and rising government and institutional funding for radiopharmaceutical production infrastructure are the primary drivers.

Copper-67 is a therapeutic radioisotope used in targeted radionuclide therapy and theranostic applications, primarily in oncology indications such as neuroendocrine tumors, prostate cancer and other solid tumors.

NorthStar Medical Radioisotopes, Nusano and Curium are among the leading companies, alongside specialized producers and developers including ITM Isotope Technologies Munich, Telix Pharmaceuticals and Orano Med.

North America leads regional demand given the United States' dense base of radiopharmaceutical manufacturing and clinical trial infrastructure, with Europe representing a significant secondary demand center tied to established nuclear medicine networks.

Inquire Before Buying Request Free Sample Ask For Discount